Results 141 to 150 of about 8,788 (204)

Greater benefits of immediate nirmatrelvir-ritonavir initiation for post-COVID outcomes: a population-based retrospective cohort study. [PDF]

Nat Commun
Chong KC, Wei Y, Wong CKH, Xiong X, Wang H, Hung CT, Li C, Yam CHK, Chow TY, Guo Z, Li K, Yang A, Mok CKP, Hui DSC, Zhao S, Yeoh EK, Lin G.   +16 more
europepmc   +1 more source

Persistent SARS-CoV-2 Infection in an Immunocompromised Host Treated Successfully With the Japanese Herbal Medicine, Mao-to: A Case Report. [PDF]

Am J Case Rep
Yamada T, Sonoda S, Otsuka M, Shirai T, Tateishi T, Furusawa H, Miyazaki Y.   +6 more
europepmc   +1 more source

Paxlovid utilization and social vulnerability: trends in Connecticut from 2022 to 2023. [PDF]

Antimicrob Steward Healthc Epidemiol
Hohenstein L, Maloney M, Banach DB.
europepmc   +1 more source

HIV Status and COVID-19 Treatment Disparities in the US National Clinical Cohort Collaborative. [PDF]

Open Forum Infect Dis
Essam Nkodo EN, Maheria P, Hurwitz E, Anzalone AJ, Li D, Islam JY, Sun J, Varley CD, Butzin-Dozier Z, Safo SE, Kirksey K, Hassan SA, Camacho-Rivera M, Patel RC, Fadul N.   +14 more
europepmc   +1 more source

A split luciferase system for studying coronavirus M^pro dimerization in vitro and in living cells. [PDF]

J Biol Chem
Delgado R, Vishwakarma J, Sanlley Hernandez JO, Tansiongco M, Cuell A, Dabrowska A, Basu R, Schmidpeter PAM, Hu Y, Tsutakawa SE, Cooley CB, Amaro RE, Harris RS.   +12 more
europepmc   +1 more source

SARS-CoV-2 Mpro inhibitor ensitrelvir: asymmetrical cross-resistance with nirmatrelvir and emerging resistance hotspots. [PDF]

Emerg Microbes Infect
Zhou Y, Gammeltoft KA, Tjørnelund-Sjursen HD, Ryberg LA, Offersgaard A, Czarnota A, Duan Z, Pham LV, Fahnøe U, Peters GHJ, Ramirez S, Bukh J, Gottwein JM.   +12 more
europepmc   +1 more source

Structural Analysis of Inhibitor Binding to the Feline Enteric Coronavirus (FECV) Main Protease. [PDF]

Viruses
Maryam A, Moquin SA, Dovala D, Kaur J, Kurt Yilmaz N, Shaqra AM, Schiffer CA.   +6 more
europepmc   +1 more source

Randomized trial of nirmatrelvir/ritonavir versus placebo for adults with acute COVID-19 to prevent long COVID: PanoramicNOR Trial. [PDF]

Trials
Blomberg B, Myklebust NN, Oppegaard O, Tøndel C, Cox RJ, Iversen A, Lehmann ME, Sandvig A, Dahl TB, Valderhaug VD, Szodoray P, Wilhelmsen M, Kirsebom BE, Glambek M, Kaarbøe O, Aukrust P, Lie RT, Langeland N.   +17 more
europepmc   +1 more source

Risk of Post-COVID-19 Conditions Among Adolescents and Adults Who Received Nirmatrelvir-Ritonavir for Acute COVID-19: A Retrospective Cohort Study. [PDF]

Open Forum Infect Dis
Dalton AF, Baca S, Raykin J, Gregory CO, Boehmer T, Koumans EH, Patel PR, Patel P, Saydah S.   +8 more
europepmc   +1 more source

A Streamlined High Performance Liquid Chromatography with Tandem Mass Spectrometry Based Workflow for Rapid Screening of Cellular Accumulation of Small Molecules. [PDF]

ChemMedChem
Metzen A, Rox K.
europepmc   +1 more source